Literature DB >> 15357673

The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma.

S-W Choi1, S-Y Park, S-P Hong, H Pai, J-Y Choi, S-G Kim.   

Abstract

BACKGROUND: Glutamate activates the N-methyl-d-aspartate (NMDA) receptors and this receptor is involved in the proliferation and migration of various tumour cells in vitro. However, the relationship between NMDA receptor expression and clinical parameters in cancer patients is unclear. Therefore, NMDA receptor 1 (NMDAR1) expression along with its clinical significance was examined in patients with oral squamous cell carcinoma (OSCC).
METHODS: Eighty-one tumour specimens from OSCC patients were used to determine the NMDAR1 expression level by immunohistochemical staining. The control was obtained from a matched normal adjacent mucosa. The cases were considered to be positive if reactivity was displayed in >25% of the cells.
RESULTS: The NMDAR1 reactivity was positive in 50 of 81 cases, while it was negative in the control. NMDAR1 expression was significantly associated with a lymph node metastasis (P = 0.008), the tumour size (P < 0.001), and the cancer stage (P = 0.034). The patients whose tumours expressed NMDAR1 had a significantly poorer survival than the patients who were NMDAR1-negative (log-rank = 6.45, d.f. = 1, P = 0.011).
CONCLUSIONS: The NMDAR1 overexpression was significantly associated with the prognosis-related factors. Therefore, it might be one of the prognostic markers of OSCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357673     DOI: 10.1111/j.1600-0714.2004.00226.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  9 in total

Review 1.  NMDA receptors on the surface of cancer cells: target for chemotherapy?

Authors:  Stephen I Deutsch; Amy H Tang; Jessica A Burket; Andrew D Benson
Journal:  Biomed Pharmacother       Date:  2014-03-27       Impact factor: 6.529

2.  The Expression of NMDA Receptor 1 Correlates with Clinicopathological Parameters in Cutaneous Squamous Cell Carcinoma.

Authors:  Minju Kang; Jae Hoon Cho; Ja Kyung Koo; Sun Up Noh; Mi-Yeon Kim; Hoon Kang; Shin Taek Oh; Hyung-Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2009-11-30       Impact factor: 1.444

Review 3.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

4.  Expression of glutamate receptor subunits in human cancers.

Authors:  Andrzej Stepulak; Hella Luksch; Christine Gebhardt; Ortrud Uckermann; Jenny Marzahn; Marco Sifringer; Wojciech Rzeski; Christian Staufner; Katja S Brocke; Lechoslaw Turski; Chrysanthy Ikonomidou
Journal:  Histochem Cell Biol       Date:  2009-06-14       Impact factor: 4.304

5.  FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801.

Authors:  Fuminori Yamaguchi; Yuko Hirata; Hossain Akram; Kazuyo Kamitori; Youyi Dong; Li Sui; Masaaki Tokuda
Journal:  BMC Cancer       Date:  2013-10-10       Impact factor: 4.430

Review 6.  Glutamate and its receptors in cancer.

Authors:  Andrzej Stepulak; Radoslaw Rola; Krzysztof Polberg; Chrysanthy Ikonomidou
Journal:  J Neural Transm (Vienna)       Date:  2014-03-09       Impact factor: 3.575

7.  MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively.

Authors:  Youguang Pu; Fangfang Zhao; Wenjing Cai; Xianghui Meng; Yinpeng Li; Shanbao Cai
Journal:  Clin Exp Metastasis       Date:  2016-02-25       Impact factor: 5.150

8.  LRFN2 binding to NMDAR inhibits the progress of ESCC via regulating the Wnt/β-Catenin and NF-κB signaling pathway.

Authors:  Yu Zhou; Lijuan Xu; Jiru Wang; Beibei Ge; Qiuzi Wang; Tao Wang; Chang Liu; Bin Wei; Qilong Wang; Yong Gao
Journal:  Cancer Sci       Date:  2022-08-08       Impact factor: 6.518

9.  Glutamate receptor, ionotropic, N‑methyl D‑aspartate‑associated protein 1 promotes colorectal cancer cell proliferation and metastasis, and is negatively regulated by miR‑296‑3p.

Authors:  Zaihua Yan; Peidong Li; Yuan Xue; Hongpeng Tian; Tong Zhou; Guangjun Zhang
Journal:  Mol Med Rep       Date:  2021-08-09       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.